On my hon. Friend’s first point about Cancer Research UK, let me be absolutely clear that it is opposed to the Bill. On the second point, what these bodies are all saying is that the Bill is unnecessary, but that if it is put in place, it would be dangerous. That would be the consequence of the Bill, and people think there are other ways of moving forward to improve access to innovative treatments.
Access to Medical Treatments (Innovation) Bill
Proceeding contribution from
Sarah Wollaston
(Conservative)
in the House of Commons on Friday, 16 October 2015.
It occurred during Debate on bills on Access to Medical Treatments (Innovation) Bill.
About this proceeding contribution
Reference
600 c575 Session
2015-16Chamber / Committee
House of Commons chamberLibrarians' tools
Timestamp
2021-11-04 13:31:29 +0000
URI
http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000195
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000195
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2015-10-16/15101634000195